Safety Study of Seneca Valley Virus in Patients With Solid Tumors With Neuroendocrine Features

Inclusion Criteria: * Patients must have a histologically confirmed solid tumor (including carcinoid) with neuroendocrine features (i.e., expression of \>= 1 of the following 3 markers: synaptophysin, chromogranin A, or CD56) that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective. * Patients must show evidence of disease progression in the three months prior to treatment with SVV-001. * Age \>= 18 years. Because no dosing or adverse event data are currently available on the use of SVV-001 in patients \<18 years of age, children are excluded from this study. Children may be eligible for future pediatric Phase I single-agent trials. * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1. * Life expectancy \>= 24 weeks. * Adequate bone marrow, hepatic, and renal function as defined below: * absolute lymphocyte count \>= 1,000/ul * absolute neutrophil count \>= 1,500/ul * platelets \>= 100,000/ul * AST/ALT \<= 2.5 x upper limit of normal (ULN) or \<= 5 x ULN if liver metastases present * total bilirubin \<= 1.5 x upper limit of normal * creatinine \<= 1.5 x upper limit of normal OR * creatinine clearance (calculated) \<= 60 mL/min/1.73 m2 for patients with creatinine \> 1.5 x upper limit of normal. * Women must have been surgically sterilized or be post-menopausal. * Men must agree to use adequate contraception (barrier method of birth control; abstinence) prior to study e…